Collaborative deals with sizeable peers happen to be a tried & tested ground...

IIPM, ADMISSIONS FOR NEW DELHI & GURGAON BRANCHES

No doubt, R&D spend has soared, but the number of new molecular entities (NMEs) and biologics approved by the FDA is definitely down. “In 2006 the US FDA approved only 22 NMEs and biologics, as comapred to 53 it approved in 1996 when R&D expenditure was less than half as of today” affirms a latest report by PwC. Moreover, “the competition from generic drug-makers has stiffened too... Collaborative deals with sizable peers happens to be a tried and tested ground as they have been doing it for long in biotech space,” analysts from global consulting firm, Frost & Sullivan shared with 4Ps, B&M.

So, whether it’s Big Pharma foresightedness or a forced outcome, one thing is for sure. Companies now seem to have recognised that even their present R&D expenditure levels are unsustainable, unless and until they deliver more proven results and cost benefits over the long term. Even if that means ‘Sleeping with the Enemy’, so be it! 4Ps

For more articles, Click on IIPM Article

Source : IIPM Editorial, 2008

An IIPM and Professor Arindam Chaudhuri (Renowned Management Guru and Economist) Initiative

For More IIPM Info, Visit below mentioned IIPM articles.
IIPM, GURGAON
ARINDAM CHAUDHURI’S 4 REASONS WHY YOU SHOULD CHOOSE IIPM...
IIPM Economy Review

Rashmi Bansal Publisher of JAMMAG magazine caught red-handed, for details click on the following links.

• Hindustan Times Article - Publisher goes underground
• Rashmi Bansal (Editor of JAMMAG)
• Rashmi Bansal (Publisher of JAMMAG)